Cost-Benefit Analysis

"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.

Descriptor ID	D003362
MeSH Number(s)	N03.219.151.125
Concept/Terms	Cost-Benefit Analysis Cost-Benefit Analysis Analyses, Cost-Benefit Analysis, Cost-Benefit Cost-Benefit Analyses Cost Benefit Analysis Analyses, Cost Benefit Analysis, Cost Benefit Cost Benefit Analyses Cost Effectiveness Cost Effectiveness Effectiveness, Cost Cost-Benefit Data Cost-Benefit Data Cost Benefit Data Data, Cost-Benefit Cost-Utility Analysis Cost-Utility Analysis Analyses, Cost-Utility Analysis, Cost-Utility Cost Utility Analysis Cost-Utility Analyses Economic Evaluation Economic Evaluation Economic Evaluations Evaluation, Economic Evaluations, Economic Marginal Analysis Marginal Analysis Analyses, Marginal Analysis, Marginal Marginal Analyses Cost Benefit Cost Benefit Costs and Benefits Benefits and Costs Cost-Effectiveness Analysis Cost-Effectiveness Analysis Analysis, Cost-Effectiveness Cost Effectiveness Analysis

Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".

Health Care [N]
Health Care Economics and Organizations [N03]
Economics [N03.219]
Costs and Cost Analysis [N03.219.151]
Cost-Benefit Analysis [N03.219.151.125]

Below are MeSH descriptors whose meaning is related to "Cost-Benefit Analysis".

Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.

Bar chart showing 144 publications over 29 distinct years, with a maximum of 13 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	2	3
1998	0	2	2
1999	0	2	2
2000	0	1	1
2001	0	1	1
2002	0	3	3
2003	0	4	4
2004	0	1	1
2005	0	4	4
2006	0	1	1
2007	0	2	2
2008	0	3	3
2009	0	5	5
2010	0	4	4
2011	0	8	8
2012	0	2	2
2013	0	8	8
2014	1	8	9
2015	1	7	8
2016	3	7	10
2017	1	8	9
2018	3	9	12
2019	1	4	5
2020	2	11	13
2021	0	6	6
2022	0	7	7
2023	0	1	1
2024	1	3	4
2025	0	6	6

Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.

Fuady A, Kasempa C, Lucas E, Nyambe N, Rao DW, Tenet V, Broutet N, Muwonge R, Mwanahamuntu M, Baussano I, Parham GP, Basu P. Economic evaluation of thermal ablation compared to cryotherapy and loop diathermy in a screen-and-treat approach to cervical cancer, Zambia. Bull World Health Organ. 2025 Sep 01; 103(9):530-540.

View in: PubMed
Sanogo V, Saud Almutairi RD, Diaby V. Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis. Expert Rev Pharmacoecon Outcomes Res. 2025 Dec; 25(10):1421-1426.

View in: PubMed
Janda K, King B, Adepoju O, Chavez S, Bejarano G, Braun RT, Ho V, Liaw W. Consolidation in an Era of Population Health and Value-Based Care: Implications for Effectiveness, Costs, and Equity. Med Care. 2025 Apr 01; 63(4):267-269.

View in: PubMed
Diaby V, Pandey S, Sanogo V, Dhayan Almutairi R, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):53-59.

View in: PubMed
Diaby V, Pandey S, Sanogo V, Almutairi RD, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):60-67.

View in: PubMed
MacLeod KE, Roy K, Wirth D, Minaya-Junca J, Onwuanyi A, Luo F, Lane R. The Program Cost Effectiveness of a Safety-Net Hospital Program Expanding Social Needs Activities in Atlanta. J Health Care Poor Underserved. 2025; 36(1):167-179.

View in: PubMed
Davis-Ewart L, Atkins L, Ghanooni D, Diaz JE, Chuku CC, Balise R, DeVries BA, Miller-Perusse M, Ackley Iii D, Moskowitz JT, McCollister K, Fardone E, Hirshfield S, Horvath KJ, Carrico AW. Supporting treatment adherence for resilience and thriving (START): protocol for a mHealth randomized controlled trial. BMC Public Health. 2024 08 29; 24(1):2350.

View in: PubMed
Qin J, Scarinci I, Lu E, Senkomago V, Ngoc Nguyen DT, Abonales L, Soin K, Edilyong J, Reichhardt M, Marfel M, Simms K, Canfell K, Maxwell K, Saraiya M, Palafox N. Building Capacity for Cervical Cancer Prevention in U.S.-Affiliated Pacific Islands: The Pacific Against Cervical Cancer Project. J Womens Health (Larchmt). 2024 Jul; 33(7):839-847.

View in: PubMed
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.

View in: PubMed
Ali AA, Kulkarni A, Bhattacharjee S, Diaby V. Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. Pharmacoeconomics. 2024 Jul; 42(Suppl 2):211-224.

View in: PubMed

People

Explore

Similar Concepts

Top Journals